Antidepressant discontinuation syndrome (ADS) is widely reported yet often minimized by terminology that obscures its status as a withdrawal phenomenon. Roughly one-third of patients using a monotherapy antidepressant develop withdrawal symptoms after discontinuation, with higher rates among patients taking venlafaxine (VEN) and those treated long-term....
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this review concerns antidepressant withdrawal pharmacology and has minimal relevance to hearing healthcare.
While antidepressants are occasionally implicated in ototoxicity (medication-related hearing damage), this review does not address hearing outcomes and carries essentially no clinical significance for audiologists.
- 01Review published in Human Psychopharmacology examines venlafaxine withdrawal mechanisms.
- 02Authors argue antidepressant discontinuation syndrome is a true withdrawal phenomenon, not relapse.
- 03No audiology-specific findings, outcomes, or patient populations are discussed.
- 04Minimal hearing-health relevance identified by indexing source.
- PMID
- 42663396
- DOI
- 10.1002/hup.70061.
- Journal
- Human Psychopharmacology: Clinical and Experimental
- Publication type
- review
- Evidence level
- 5
- Population
- Not applicable — narrative review of pharmacological literature on venlafaxine withdrawal
- Intervention
- Venlafaxine discontinuation / antidepressant withdrawal
Primary outcomes
Psychopharmacological mechanisms underlying antidepressant discontinuation syndrome